The Return Of The Advisory Committee: US FDA Has Busy Fall Ahead

 
• By Michael McCaughan

The prototypical US FDA advisory committee review of a pending new drug application has become something of an endangered species. A suddenly busy October and November agenda suggests that might be changing.

virtual meeting
For the first time in a while, FDA watchers have a busy upcoming advisory committee schedule. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers